Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Share-based Compensation: 2016-2024

Historic Share-based Compensation for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Dec 2024 value amounting to $69.4 million.

  • Crinetics Pharmaceuticals' Share-based Compensation rose 25.10% to $22.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $88.1 million, marking a year-over-year increase of 41.81%. This contributed to the annual value of $69.4 million for FY2024, which is 69.49% up from last year.
  • As of FY2024, Crinetics Pharmaceuticals' Share-based Compensation stood at $69.4 million, which was up 69.49% from $40.9 million recorded in FY2023.
  • Over the past 5 years, Crinetics Pharmaceuticals' Share-based Compensation peaked at $69.4 million during FY2024, and registered a low of $10.4 million during FY2020.
  • Moreover, its 3-year median value for Share-based Compensation was $40.9 million (2023), whereas its average is $46.2 million.
  • Data for Crinetics Pharmaceuticals' Share-based Compensation shows a peak YoY soared of 69.49% (in 2024) over the last 5 years.
  • Crinetics Pharmaceuticals' Share-based Compensation (Yearly) stood at $10.4 million in 2020, then skyrocketed by 66.41% to $17.4 million in 2021, then soared by 62.91% to $28.3 million in 2022, then spiked by 44.82% to $40.9 million in 2023, then soared by 69.49% to $69.4 million in 2024.